Gynecologic and hormonal effects of raloxifene in premenopausal women Ahalya Premkumar, M.D., David J. Venzon, Ph.D., Nilo Avila, M.D., Diane V. Johnson, R.T., R.D.M.S., Alan T. Remaley, M.D., Ph.D., Michele R. Forman, Ph.D., M.S., Jennifer Eng-Wong, M.D., M.P.H., JoAnne Zujewski, M.D., Pamela Stratton, M.D. Fertility and Sterility Volume 88, Issue 6, Pages 1637-1644 (December 2007) DOI: 10.1016/j.fertnstert.2007.01.095 Copyright © 2007 American Society for Reproductive Medicine Terms and Conditions
Figure 1 Ovarian stimulation. (A) Transvaginal sonogram with color Doppler shows bilateral corpora lutea. (B) Large bilateral ovarian cysts seen in a subject on raloxifene. Fertility and Sterility 2007 88, 1637-1644DOI: (10.1016/j.fertnstert.2007.01.095) Copyright © 2007 American Society for Reproductive Medicine Terms and Conditions
Figure 2 Uterine polyps. Saline infusion sonohysterogram at 12 months after raloxifene shows multiple endometrial polyps (arrows). Fertility and Sterility 2007 88, 1637-1644DOI: (10.1016/j.fertnstert.2007.01.095) Copyright © 2007 American Society for Reproductive Medicine Terms and Conditions